Almotriptan Malate is a triptan drug discovered and developed by Almirall for the treatment of heavy migraine headache. Almotriptan is a Serotonin-1b and Serotonin-1d Receptor Agonist. Binding of the drug to the receptor leads to vasoconstriction of the cranial blood vessels and thus affects the redistribution of cranial blood flow. Almotriptan significantly increases cerebral blood flow and reduces blood flow through extracerebral cranial vessels. Even though it affects cranial blood vessels a single dose of almotriptan (12.5 mg) has no clinically significant effect on blood pressure or heart rate in both young and elderly healthy volunteers.